The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Recce Pharmaceuticals (ASX:RCE) has confirmed its completion of the latest fast-infusion study using its R327 anti-infective as an IV drug.

Notably, this time, the company has wrapped up a test that saw the fastest infusion times to date yet tested on patients.

The company touts its flagship R327 as an alternative antibiotic treatment (“anti-infective”) with a wide range of applications. Today’s news relates to a Urinary Tract Infection (UTI) trial, but the company is also exploring the use of the compound on post-diabetic surgery wound infections.

Six patients took place in the latest fast-infusion trial with recipients being dosed with 4000mg via IV drip.

The value proposition behind these trials is that infusion took only 20 minutes – a far cry from the first trials which took far longer. The company is, in short, seeing how quickly it can fill someone up with R327 – and kill off UTI in a one-dose sitting.

To this end, a safety committee will now review the latest (and pre-existing) trial data towards producing a report outlining the product’s risks, if any are detected. These procedures are required for full-fledged greenlight down the line.

That committee is set to report back within six weeks.

“We have successfully reached a new milestone in this trial by administering a 4,000mg dose over a fast 20-minute infusion to all subjects, the highest dosage achieved so far in this clinical trial,” Recce CEO James Graham said.

“This is a significant step forward in bringing us closer to establishing R327 as a leading treatment for those suffering from UTI/Urosepsis.”

RCE last traded at 57cps.

RCE by the numbers
More From The Market Online
The Market Online Video

ASX Daily Close: ASX matches futures prediction on a green Friday | 21 June 2024

The ASX200 reversed its trend to end the week in the green, up 0.35%. Nearly all…
The Market Online Video

ASX Market Update: Stocks swing from green with energy to remorseful red | 21 June, 2024

The ASX200 came out the gate in the green on Friday, but slipped well below the red line within the first hour of

Week 25 Wrap: No RBA cut yet; India stocks shake off Modi jitters; China concerns remain

The RBA keeps rates on pause; Guzman Gomez falls nearly -5% on Friday; Droneshield's new ATH;…

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

The one defining feature of our post-COVID 'new normal' is a USA swing towards domestic supply…